Work

Abstract CT277: IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC)

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct277

Authors: Jason Mouabbi, Paula Pohlmann, Rachel Layman, Roland Bassett, Lavinia Middleton, Bora Lim, Toni Zaayman, Krystle Nomie, Evgeny Barykin, Anastasiya Evdokimova, Mariana Chavez-MacGregor, Jennifer Litton, Sharon Giordano, Funda Meric-Bernstam

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154738296

Cites:

Cited by:

Related to: